Recap: Iterum Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Iterum Therapeutics (NASDAQ:ITRM) reported Q3 earnings with an EPS of $-1.2, missing estimates by 31.87% compared to the expected $-0.91. Revenue was unchanged from the same period last year. Previously, the company beat EPS estimates by $0.03, which led to a 7.92% share price increase the following day.
November 14, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Iterum Therapeutics reported a larger than expected Q3 loss with an EPS of $-1.2, missing the estimate by 31.87%. The revenue remained the same as last year's comparable quarter.
Missing earnings estimates typically results in negative investor sentiment and can lead to a decrease in stock price. The previous quarter's beat and subsequent stock price increase may not be enough to offset the negative impact of the current earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100